Trial Profile
A phase I trial of intranasal peptide T: safety, toxicity, and pharmacokinetics in human immunodeficiency virus-1 (HIV-1) infected patients.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Peptide T (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 22 Nov 2005 New trial record.